Excitatory Catatonia: Symptoms, Causes, and Treatment

Excitatory catatonia is a form of catatonia in which the dominant features are prolonged, purposeless psychomotor agitation rather than the frozen stillness most people associate with the condition. While the retarded (or “stuporous”) subtype involves immobility, mutism, and staring, excited catatonia produces relentless motor activity, impulsive behavior, and sometimes dangerous aggression that can look deceptively like mania or psychotic agitation.¹ That resemblance to other psychiatric emergencies is part of what makes excitatory catatonia so treacherous: it is frequently misidentified, and the wrong treatment can make it worse.

What Excitatory Catatonia Looks Like

The symptoms of excitatory catatonia share a common thread: motor and behavioral excess that appears involuntary and poorly directed. Someone in this state may pace ceaselessly, flail their limbs, shout repetitive phrases, undress, or lash out at caregivers without any clear provocation. The agitation does not follow a logical emotional arc the way anger or panic does; it often has a mechanical, driven quality that continues for hours or days at a time. Alongside this motor storm, you may see stereotypies (the same movement repeated over and over), echolalia (parroting back what others say), and echopraxia (mirroring others’ movements).

Autonomic instability frequently accompanies the excited form. Heart rate, blood pressure, and body temperature can swing unpredictably. Sweating and flushing are common. When fever, severe rigidity, and autonomic chaos converge, the condition shades into what clinicians call malignant catatonia, which is a medical emergency with a real risk of death if untreated.² The line between “excited” and “malignant” is not always obvious, and clinicians watch autonomic signs closely because they signal when the situation is escalating beyond what the body can safely sustain.

One counterintuitive feature worth knowing: patients in excitatory catatonia may abruptly swing into stupor and back again within the same episode. Catatonia is not always either excited or retarded; some people oscillate between extremes or display features of both simultaneously. Factor analyses of catatonia rating data have confirmed that retarded and excited presentations cluster into distinct symptom groups, but individual patients do not always land neatly in one cluster.³

Why It Gets Mistaken for Other Conditions

Excitatory catatonia is one of the most commonly misdiagnosed psychiatric emergencies because, on the surface, it looks like several other things. A person who is agitated, talking rapidly, and behaving impulsively could be in a manic episode, in the throes of stimulant intoxication, or delirious from a medical illness. The overlap with delirium is especially dangerous in younger patients with autoimmune brain inflammation, where excited catatonia can be the primary manifestation.⁴

Distinguishing excitatory catatonia from neuroleptic malignant syndrome (NMS) is another persistent challenge. NMS is a serious reaction to antipsychotic medications that produces muscle rigidity, altered consciousness, fever, and autonomic dysfunction. Malignant catatonia produces strikingly similar signs. Case reports repeatedly describe clinicians struggling to tell the two apart, and the stakes are high because their treatments diverge: NMS calls for stopping the offending antipsychotic and providing supportive care, while catatonia calls for benzodiazepines and possibly electroconvulsive therapy.⁵ In practice, careful history-taking (was an antipsychotic recently started or increased?) and close attention to the sequence of symptom onset often guide the distinction.⁶

The diagnostic confusion matters beyond academic interest. When excitatory catatonia is misread as psychosis or mania and treated with antipsychotics, the drugs can worsen the catatonia or, in the worst case, push it toward malignant catatonia. This is one of the most important practical reasons to get the diagnosis right early.

What Triggers Excitatory Catatonia

Catatonia was historically viewed as a feature of schizophrenia, and for much of the twentieth century, diagnostic manuals treated it as inseparable from that diagnosis. The reality that emerged over the past few decades is broader. ICD-10 began acknowledging catatonia in medical conditions, and ICD-11 now treats catatonia as an independent disorder with a common clinical picture regardless of the underlying condition.⁷ This shift reflects a substantial body of evidence showing that catatonia, including the excited subtype, arises from many different causes.

Mood disorders are at least as common a trigger as schizophrenia. One study of psychiatric inpatients found catatonia in roughly one in ten patients, with no difference in prevalence between those diagnosed with schizophrenia and those diagnosed with mood disorders like bipolar disorder or major depression.³ Excitatory catatonia in bipolar disorder can be particularly confusing because the agitation mirrors a severe manic episode so closely.

Medical and neurological conditions also produce catatonia. Anti-NMDA receptor encephalitis, an autoimmune condition in which the body’s immune system attacks a specific receptor in the brain, has become one of the best-recognized medical triggers. It typically strikes adolescents and young adults and can produce excited catatonia as a prominent feature, alongside seizures and movement abnormalities.⁴ Infections, metabolic disturbances, withdrawal from alcohol or sedatives, and substance use (including cannabis in rare cases) have all been documented as catatonia triggers.²

What Is Happening in the Brain

The neurobiology of catatonia is still being pieced together, and no single mechanism fully accounts for the syndrome. Neuroimaging research has pointed toward a breakdown in how the brain’s movement-planning regions communicate with the motor cortex. EEG studies in catatonic patients have found delayed electrical signals over the frontal and parietal midline areas during movement preparation, suggesting that the coupling between premotor areas (which plan a movement) and motor areas (which execute it) is not working properly.⁸

This disruption helps explain why catatonia can look so different from one patient to the next. If the system that regulates voluntary movement loses its normal “braking” and “accelerating” controls, you could see either freezing (when the brakes are stuck on) or the runaway motor activity of excited catatonia (when they are stuck off). GABA, the brain’s main inhibitory chemical messenger, is thought to play a central role. This is consistent with why benzodiazepines, which boost GABA activity, are so effective as a treatment. The involvement of other neurotransmitter systems, including glutamate and dopamine, likely explains why the picture gets more complicated in some patients.

An older but influential theoretical framework has proposed that catatonia may be rooted in an ancient fear response. In this view, the retarded form resembles tonic immobility, the “playing dead” strategy seen across the animal kingdom, while the excited form may represent a panicked flight-like state that the brain cannot shut off.⁹ Whether or not this evolutionary lens captures the full picture, it resonates with the clinical observation that fear and anxiety are almost universally present in catatonic patients when they are later able to describe their experience.

How Clinicians Identify It

Diagnosing catatonia formally requires a clinician to identify a minimum number of characteristic signs. Under DSM-5, a patient must show at least three of twelve recognized catatonic signs. ICD-11 uses a similar threshold, requiring three of fifteen signs.¹⁰ The most commonly used structured assessment tool is the Bush-Francis Catatonia Rating Scale (BFCRS), a 23-item scale with a shorter 14-item screening version. When researchers tested the screening instrument’s accuracy, a threshold of just two signs detected catatonia with perfect sensitivity and very high specificity.¹¹ The original scale was designed with good inter-rater reliability, meaning different clinicians scoring the same patient tend to agree on the results.¹²

In practice, though, catatonia remains underdiagnosed. Many emergency department and general medical ward clinicians are not trained to look for it, and the excited form in particular slips through the cracks because the patient does not “look catatonic” in the popular sense. When researchers have studied the specificity of individual signs, only catalepsy and waxy flexibility (both features more characteristic of retarded catatonia) have high diagnostic specificity. Excited signs like purposeless agitation and repetitive speech, while core features, are less specific on their own because they overlap with so many other conditions.¹⁰ This means diagnosing excitatory catatonia often depends on pattern recognition and clinical suspicion as much as it does on checking boxes on a rating scale.

Treatment with Benzodiazepines

Benzodiazepines, especially lorazepam, are the first-line treatment for catatonia across all subtypes, including the excited form. The “lorazepam challenge test” serves a dual purpose: it is both a diagnostic aid and the beginning of treatment. A dose of lorazepam given intravenously often produces a rapid and dramatic reduction in catatonic signs, sometimes within minutes. This response is considered highly characteristic of catatonia and helps clinicians distinguish it from conditions that look similar but would not respond the same way.¹³

The dose used for the challenge test has been a matter of some debate. A study comparing 2 mg and 4 mg intravenous lorazepam found that both doses produced significant improvement in catatonic signs, but the lower dose actually resolved certain individual signs (like stupor, mutism, rigidity, and negativism) more clearly than the higher one.¹⁴ In ongoing treatment, lorazepam doses can be titrated upward considerably, sometimes to levels that would be considered high by other standards, because catatonic patients often tolerate and require more.

For excitatory catatonia specifically, the benzodiazepine response can seem paradoxical to anyone who is not familiar with the condition: giving a sedative to someone who is already thrashing and agitated produces a calming effect that looks less like sedation and more like a genuine resolution of the underlying motor disturbance. This is because the medication is not just calming the patient down; it is addressing the GABA-related circuit dysfunction driving the abnormal motor output.

When Benzodiazepines Are Not Enough

Electroconvulsive therapy (ECT) is the most effective treatment for catatonia that does not respond to benzodiazepines. Systematic reviews report response rates ranging from 80% to 100%, which represents some of the strongest treatment outcomes in all of psychiatry.¹⁵ For excitatory catatonia in particular, ECT is often recommended as first-line treatment (alongside benzodiazepines) rather than as a fallback, especially when the presentation is severe or when signs of malignant catatonia are emerging.

Despite this evidence, access to ECT remains frustratingly limited. Legal restrictions in some jurisdictions, stigma among patients and families, and logistical challenges (ECT requires anesthesia support and specialized equipment) all create barriers. Experts in the field have consistently called this gap between evidence and access one of the most significant obstacles in catatonia care.¹⁶ In some settings, patients with benzodiazepine-resistant excited catatonia wait days or longer for ECT access while their condition deteriorates.

Research on catatonia treatment overall is scarce relative to the severity of the condition. Beyond lorazepam and ECT, evidence for other pharmacological options is largely anecdotal or based on small case series.¹⁷ Some clinicians have tried NMDA receptor modulators like amantadine and memantine, particularly when autoimmune encephalitis is the underlying cause, but these remain off-label and poorly studied in controlled settings.

Physical Complications and Why They Are Dangerous

Excitatory catatonia is not just a psychiatric problem; it is a medical one. Prolonged agitation places enormous stress on the body. Rhabdomyolysis, in which sustained muscle overactivity causes muscle tissue to break down and release proteins that can damage the kidneys, is a well-recognized complication. This can progress to acute kidney injury if not caught.¹⁸ Deep vein thrombosis (blood clots in the legs), pneumonia from aspiration or immobility during periods of stupor, and pressure injuries are also significantly more common in catatonic patients. Research on patients with anti-NMDA receptor encephalitis found that those who developed catatonia were more likely to need intensive care and to develop these complications compared to those without catatonia.¹⁹

When excitatory catatonia escalates into the malignant form, with high fever and severe autonomic instability, the situation can become life-threatening. Clinical teams increasingly recognize that these patients benefit from early collaboration between psychiatry and critical care medicine rather than management on a psychiatric ward alone.²⁰ The ability to monitor cardiac rhythm, provide IV fluids for rhabdomyolysis, and manage airway complications makes an ICU setting appropriate for the most severe cases.

Excitatory Catatonia in Autism

One population in which excited catatonia is increasingly recognized is people with autism spectrum disorder. Case series have described autistic individuals developing catatonic episodes dominated by agitation, unprovoked aggression, stereotypic behaviors, urinary incontinence, and compulsive behaviors.²¹ The overlap between autistic stereotypies and catatonic stereotypies creates a diagnostic gray zone: how do you tell whether a sudden increase in repetitive behavior represents a worsening of baseline autism features or the onset of a new catatonic episode?

This distinction matters because catatonia responds to specific treatments (benzodiazepines, ECT), while a worsening of autistic traits does not respond to those same interventions in the same way. Clinicians working with autistic patients have learned to watch for acute changes in the pattern of behavior, especially the sudden emergence of aggression, loss of previously acquired skills, or new incontinence, as red flags for possible catatonia. The reclassification of catatonia in ICD-11 as a condition that can arise in the context of any psychiatric disorder, including autism, has helped legitimize this diagnostic thinking.⁷

Relapse and Long-Term Outlook

Catatonia is not always a one-time event. Recent research has found that close to half of patients experience at least one relapse, with the highest risk concentrated in the first two years after the initial episode.²² The median time to recurrence among those who did relapse was about six and a half years in one study, suggesting that some patients go through long periods of remission before a second episode hits.²³

What keeps it from coming back? The evidence is still preliminary, but benzodiazepine maintenance therapy has been consistently associated with a lower risk of recurrence, cutting the hazard roughly in half in one analysis.²³ Antipsychotic use showed a more complicated pattern: it appeared protective in the first 60 days after an episode but was associated with a higher recurrence risk beyond that window.²³ This finding is provocative because it mirrors the clinical concern that antipsychotics, while sometimes necessary for the underlying psychiatric condition, may carry a particular risk in catatonia-prone individuals over the long term. The JAMA Psychiatry analysis, by contrast, suggested that antipsychotic treatment could play a role in relapse prevention, particularly in the first two years.²² The disagreement highlights how early the field is in understanding maintenance treatment for catatonia.

For patients and families, the practical takeaway is that a single episode of excited catatonia should prompt a conversation about long-term management. Treating the underlying psychiatric or medical condition aggressively, maintaining benzodiazepine therapy for a period after resolution, and having a clear plan for recognizing early signs of recurrence all appear to matter. Given the severity of the condition and the speed at which it can escalate, preparedness counts for a great deal.

The Antipsychotic Paradox

One of the most clinically important and least intuitive aspects of catatonia management is the complicated role of antipsychotic medications. These drugs are standard treatment for many of the psychiatric conditions that underlie catatonia, including schizophrenia and bipolar disorder with psychotic features. Yet in the acute phase of catatonia, antipsychotics can be harmful. They can worsen catatonic signs, and in some patients they precipitate the transition from excited catatonia to the malignant form. The clinical presentation of NMS, which is itself an antipsychotic side effect, overlaps so heavily with malignant catatonia that some researchers have argued they may be the same condition expressing itself differently depending on the context.⁵

This creates a genuine dilemma. A patient with schizophrenia who develops excited catatonia needs the catatonia treated, but also eventually needs their psychotic disorder managed, and the main tool for that job is the very class of drug that could worsen the catatonia. In practice, most clinicians stop or reduce antipsychotics during the acute catatonic episode, treat with benzodiazepines and ECT as needed, and then cautiously reintroduce antipsychotics once the catatonia has resolved, sometimes choosing a different agent than the one the patient was taking before. The recurrence data suggesting that antipsychotics may be protective in the short term but risky over longer periods adds another layer of uncertainty to these decisions.²³ There is no clean algorithm here, and experienced clinicians often describe managing catatonia-prone patients as an ongoing balancing act rather than a decision that gets settled once.

1
PubMed Central. Catatonia: Our current understanding of its diagnosis, treatment and pathophysiology
2
PubMed Central. Cannabis-Induced Catatonia Complicated by Rhabdomyolysis, Acute Kidney Injury, and Sympathetic Overactivity: A Case Report
3
PubMed. Catatonia in inpatients with psychiatric disorders: A comparison of schizophrenia and mood disorders
4
PubMed. Adolescents and Young Adults With Anti-N-methyl-D-aspartate Receptor Encephalitis With Excited Catatonia: Literature Review and 2 Illustrative Cases
5
PubMed Central. Malignant Catatonia Versus Neuroleptic Malignant Syndrome
6
PubMed Central. Catatonia versus neuroleptic malignant syndrome: the diagnostic dilemma and treatment
7
PubMed Central. Catatonia in ICD-11
8
PubMed Central. Structure and neural mechanisms of catatonia
9
PubMed Central. “Scared stiff”: catatonia as an evolutionary-based fear response
10
PubMed. Gaps and Controversies in Catatonia as a Movement Disorder
11
PubMed. Diagnosing catatonia and its dimensions: Cluster analysis and factor solution using the Bush Francis Catatonia Rating Scale (BFCRS)
12
PubMed. Catatonia. I. Rating scale and standardized examination
13
PubMed Central. Lorazepam challenge test: A unique clinical response in catatonia
14
PubMed. Revisiting lorazepam challenge test: Clinical response with dose variations and utility for catatonia in a psychiatric emergency setting
15
PubMed Central. Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response
16
PubMed Central. Electroconvulsive Therapy for Patients with Catatonia: Current Perspectives
17
PubMed Central. A clinical review of the treatment of catatonia
18
Annals of Palliative Medicine. Catatonia in the medically ill and dying: a review for palliative care clinicians
19
PubMed Central. Catatonia in adult anti-NMDAR encephalitis: an observational cohort study
20
PubMed Central. Malignant Catatonia Warrants Early Psychiatric-Critical Care Collaborative Management: Two Cases and Literature Review
21
PubMed Central. Excited Catatonia in Autism Spectrum Disorder: A Case Series
22
JAMA Psychiatry. Risk Factors for Catatonia Relapse in Psychotic and Affective Disorders
23
PubMed Central. Catatonia Treatments and Risk of Recurrence